Pacira BioSciences Stock Forecast for 2023 - 2025 - 2030

Updated on 02/04/2023

Stock Rating
16
Price Target
$78.00
Consensus
Outperform
Upside
86.34%
Analysts
6
Stock Rating
16
Upside
86.34%
Analysts
6
Price Target
$78.00

Pacira BioSciences Stock Forecast and Price Target

If the average 2023 price target of $78.00 recently set by six prominent experts for Pacira BioSciences is met, there would be a potential upside of approximately 86.34% from the last closing price in February, 2023. The high estimate is $94.00, and the low is $54.00. If you're not interested in PCRX stock, you may be interested in its competitors.

$78.00

86.34% Upside

Outperform
Outperform

Pacira BioSciences Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Pacira BioSciences's Price has grown, increasing from $45.26 to $81.30 – an increase of 79.64%. For the following year, the 0 analysts predict that Pacira BioSciences's Fair Value will drop by 25.70%, reaching $60.41. In 2030, the professionals' prediction is that PCRX's Fair Value will decrease by 21.44%, reaching $63.87.

2022 Fair Value Forecast
$60.41
2023 Fair Value Forecast
$57.15
2024 Fair Value Forecast
$59.81
2025 Fair Value Forecast
$66.95
2026 Fair Value Forecast
$64.85
2027 Fair Value Forecast
$62.29
2028 Fair Value Forecast
$61.60
2029 Fair Value Forecast
$63.34
2030 Fair Value Forecast
$63.87
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 11
$164.61 Buy/Sell $181.05 9.65%
PFE Stock Forecast Pfizer Inc Outperform 3
$44.06 Buy/Sell $53.97 19.50%
ABT Stock Forecast Abbott Laboratories Outperform 10
$111.79 Buy/Sell $120.97 11.82%
SYK Stock Forecast Stryker Corp Outperform 10
$283.14 Buy/Sell $251.20 -8.17%
BSX Stock Forecast Boston Scientific Outperform 15
$48.50 Buy/Sell $50.77 3.09%

Pacira BioSciences Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Pacira BioSciences's Revenue has grown, increasing from $421.03M to $541.53M – an increase of 28.62%. For the following year, the 0 analysts predict that Pacira BioSciences's Revenue will drop by 14.44%, reaching $463.32M. In 2030, the professionals' prediction is that PCRX's Revenue will decrease by 13.01%, reaching $471.09M.

2022 Rev Forecast
$0.46B
2023 Rev Forecast
$0.45B
2024 Rev Forecast
$0.45B
2025 Rev Forecast
$0.48B
2026 Rev Forecast
$0.48B
2027 Rev Forecast
$0.47B
2028 Rev Forecast
$0.46B
2029 Rev Forecast
$0.47B
2030 Rev Forecast
$0.47B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BAX Stock Forecast Baxter International Outperform 17
$46.68 Buy/Sell $62.83 24.25%
TFX Stock Forecast Teleflex Outperform 13
$258.47 Buy/Sell $373.20 -1.34%
AMBU B Stock Forecast Ambu A/S Hold 18
kr65.76 Buy/Sell kr94.25 45.23%

Pacira BioSciences Dividend per Share Forecast for 2023 - 2025 - 2030

Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
IRWD Stock Forecast Ironwood Pharmaceuticals Hold 14
$11.40 Buy/Sell $12.60 9.65%
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$41.61 Buy/Sell $35.50 -18.29%
AVNS Stock Forecast Avanos Medical Hold 11
$31.59 Buy/Sell $43.00 9.21%

Pacira BioSciences Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, Pacira BioSciences's Free Cash Flow has grown by 45.66%, from $60.36M to $87.92M. According to the 0 analysts polled, in the next year, Pacira BioSciences's Free Cash Flow will fall by 18.97%, reaching $71.24M. By 2030, professionals believe that Pacira BioSciences's Free Cash Flow will have decreased by 17.29%, falling to $72.72M.

2022 FCF Forecast
$0.07B
2023 FCF Forecast
$0.08B
2024 FCF Forecast
$0.07B
2025 FCF Forecast
$0.07B
2026 FCF Forecast
$0.07B
2027 FCF Forecast
$0.07B
2028 FCF Forecast
$0.07B
2029 FCF Forecast
$0.07B
2030 FCF Forecast
$0.07B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
MNKP.F Stock Forecast Mallinckrodt - 12
$19.00 Buy/Sell $1.50 9.11%
COLL Stock Forecast Collegium Pharmaceutical Buy 11
$28.59 Buy/Sell $27.50 1.43%
NasdaqGS:BDSI Stock Forecast BioDelivery Sciences Internati... - 11
$5.59 Buy/Sell $10.00 78.89%

Pacira BioSciences Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Pacira BioSciences's Net Income has grown, increasing from $-11.02M to $41.98M – a growth of 480.94%. The next year looks promising for Pacira BioSciences, with analysts predicting Net Income of $95.95M – an increase of 128.57%. Over the next nine years, experts anticipate that Pacira BioSciences's Net Income will grow at a rate of 219.31%.

2022 NI Forecast
$0.10B
2023 NI Forecast
$0.12B
2024 NI Forecast
$0.19B
2025 NI Forecast
$0.12B
2026 NI Forecast
$0.12B
2027 NI Forecast
$0.13B
2028 NI Forecast
$0.15B
2029 NI Forecast
$0.14B
2030 NI Forecast
$0.13B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ANIP Stock Forecast ANI Pharmaceuticals Outperform 13
$44.67 Buy/Sell $61.67 0.74%
ASRT Stock Forecast Assertio Holdings Outperform 8
$4.10 Buy/Sell $5.83 46.34%
ACRX Stock Forecast AcelRx Pharmaceuticals Outperform 6
$0.29 Buy/Sell $4.25 1279.31%

Pacira BioSciences EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Pacira BioSciences's EBITDA has grown from $55.29M to $161.38M – a 191.88% increase. For the next year, 0 analysts project Pacira BioSciences's EBITDA to drop by 44.78%, reaching $89.11M. By 2030, professionals believe that Pacira BioSciences's EBITDA will decrease by 32.65%, reaching $108.69M – a concerning trend for the company.

2022 EBITDA Forecast
$0.09B
2023 EBITDA Forecast
$0.09B
2024 EBITDA Forecast
$0.10B
2025 EBITDA Forecast
$0.12B
2026 EBITDA Forecast
$0.11B
2027 EBITDA Forecast
$0.10B
2028 EBITDA Forecast
$0.10B
2029 EBITDA Forecast
$0.11B
2030 EBITDA Forecast
$0.11B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
AQST Stock Forecast Aquestive Therapeutics Outperform 0
$2.93 Buy/Sell $0.00 241.30%
TRVN Stock Forecast Trevena Outperform 2
$0.36 Buy/Sell $5.18 872.22%
CPIX Stock Forecast Cumberland Pharmaceuticals - 0
$2.23 Buy/Sell $0.00 10.76%

Pacira BioSciences EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Pacira BioSciences's EBIT has grown by 272.00%, rising from $35.71M to $132.84M. According to 0 prominent analysts, Pacira BioSciences's EBIT will fall by 51.11% in the next year, reaching $64.94M. By 2030, professionals believe that Pacira BioSciences's EBIT will decrease by 34.86%, reaching $86.54M – a concerning trend for the company.

2022 EBIT Forecast
$0.06B
2023 EBIT Forecast
$0.07B
2024 EBIT Forecast
$0.08B
2025 EBIT Forecast
$0.10B
2026 EBIT Forecast
$0.09B
2027 EBIT Forecast
$0.08B
2028 EBIT Forecast
$0.08B
2029 EBIT Forecast
$0.09B
2030 EBIT Forecast
$0.09B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ACOR Stock Forecast Acorda Therapeutics - 5
$0.45 Buy/Sell $5.00 11.11%
BXRX Stock Forecast Baudax Bio Buy 0
$0.74 Buy/Sell $0.00 981.08%
MDT Stock Forecast Medtronic Outperform 11
$80.59 Buy/Sell $90.05 6.71%

Pacira BioSciences EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, Pacira BioSciences's EPS has grown, increasing from $1.67 to $3.00 – an increase of 79.64%. For the following year, the 0 analysts predict that Pacira BioSciences's EPS will drop by 25.70%, reaching $2.23. In 2030, the professionals' prediction is that PCRX's EPS will decrease by 21.44%, reaching $2.36.

2022 EPS Forecast
$2.23
2023 EPS Forecast
$2.11
2024 EPS Forecast
$2.21
2025 EPS Forecast
$2.47
2026 EPS Forecast
$2.39
2027 EPS Forecast
$2.30
2028 EPS Forecast
$2.27
2029 EPS Forecast
$2.34
2030 EPS Forecast
$2.36